OGN

In April 2026, Organon agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in cash, which significantly boosted the stock's momentum, and analysts upgraded OGN with a positive outlook. In July 2026, Organon announced a quarterly dividend of $0.02 per share. In August 2026, the company opened a Risk Evaluation and Mitigation Strategy (REMS) program for MIUDELLA®, a hormone-free intrauterine device, in anticipation of its commercial availability. In September 2026, the U.S. FDA accepted for review a supplemental New Drug Application for MIUDELLA®, seeking to extend its approved duration of use from 3 to 6 years, which is seen as a positive for Organon's women's health portfolio. Overall, the stock price has seen a substantial increase, rising 32.95% over the last 12 months and 92.19% year-to-date as of September 4, 2026.